<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01520740</url>
  </required_header>
  <id_info>
    <org_study_id>03-C11-004PLV</org_study_id>
    <nct_id>NCT01520740</nct_id>
  </id_info>
  <brief_title>Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema</brief_title>
  <acronym>CV+/-</acronym>
  <official_title>Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeris Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aeris Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of baseline collateral ventilation status on outcomes
      following treatment with AeriSeal System in patients with advanced upper-lobe predominant
      heterogenous emphysema.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in group mean post bronchodilator Forced Exhalation Volume in one second (FEV1)</measure>
    <time_frame>24 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in group mean 6 Minute Walk Test (6MWT) distance</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in group mean health related quality of life</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from baseline in group mean health related quality of life, measured in terms of St. George's Respiratory Questionnaire (SGRQ) total domain score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pulmonary Emphysema</condition>
  <arm_group>
    <arm_group_label>Collateral Ventilation Positive (CV+)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Collateral Ventilation Negative (CV-)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Emphysematous Lung Sealant</intervention_name>
    <description>4 Subsegments treated - 2 each bilaterally</description>
    <arm_group_label>Collateral Ventilation Positive (CV+)</arm_group_label>
    <other_name>AeriSeal System Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Emphysematous Lung Sealant</intervention_name>
    <description>4 Subsegments treated - 2 each bilaterally</description>
    <arm_group_label>Collateral Ventilation Negative (CV-)</arm_group_label>
    <other_name>AeriSeal System Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide informed consent and to participate in the study

          -  Age &gt; or = 40 years at the time of the screening

          -  Advanced upper lobe predominant emphysema by CT scan

          -  Two (2) subsegments appropriate for treatment based upon CT scan in 2 different upper
             lobe segments in each lung (total 4 available subsegments)

          -  MRCD questionnaire score of 2 or greater at screening

          -  Failure of medical therapy to provide relief of symptoms

          -  Spirometry 15 minutes after administration of bronchodilator (BOTH):

               -  FEV1 &lt; 50% predicted

               -  FEV1/FVC ratio &lt; 70%

          -  Lung volumes by plethysmography (BOTH):

               -  TLC &gt; 100% predicted

               -  RV &gt; 150% predicted

          -  DLco &gt; or = 20 and &lt; or = 60% predicted

          -  Oxygen saturation (SpO2) &gt; 90% on &lt; or = 4 L/min supplemental O2, at rest

          -  Six-Minute Walk Test distance &gt; or = 150 m

          -  Abstinence from smoking for at least 16 weeks prior to screening

        Exclusion Criteria:

          -  Prior lung volume reduction surgery, prior lobectomy or pneumonectomy, prior lung
             transplantation, prior airway stent placement, prior pleurodesis, or prior
             endobronchial lung volume reduction therapy of any type

          -  Requirement for ventilator support (invasive or non-invasive)

          -  Three (3) or more COPD exacerbations requiring hospitalization within 1 year of
             Screening visit or a COPD exacerbation requiring hospitalization within 8 weeks of
             Screening visit

          -  α-1 antitrypsin serum level of &lt;80 mg/dl (immunodiffusion) or &lt;11µmol/L (nephelometry)
             at Screening visit in the absence of enzyme replacement therapy. Patients with
             documented α-1 antitrypsin deficiency requiring replacement therapy are excluded from
             the study participation.

          -  Pulmonary hypertension, defined as:

               -  Echocardiogram with estimated peak systolic pressure &gt; 45 mmHg in the presence of
                  tricuspid valve regurgitation stated in the echocardiogram report

               -  If the echocardiogram shows peak systolic pressure &gt; 45 mmHg, right heart
                  catheterization is required to rule out pulmonary hypertension, defined as peak
                  systolic pressure &gt; 45 mmHg or mean pressure &gt; 35 mmHg

          -  Clinically significant asthma (reversible airway obstruction) or bronchiectasis

          -  CT scan: Presence of the following radiologic abnormalities:

               -  Pulmonary nodule on CT scan greater that 1.0 cm in diameter (Does not apply if
                  present for 2 years or more without increase in size or if proven benign by
                  biopsy/PET)

               -  Radiologic picture consistent with active pulmonary infection, e.g., unexplained
                  parenchymal infiltrate

               -  Significant interstitial lung disease

               -  Significant pleural disease

               -  Giant bullous disease (a predominant bulla &gt; 10 cm in diameter)

          -  Use of systemic steroids &gt; 20 mg/day or equivalent, immunosuppressive agents,
             heparins, oral anticoagulants (e.g., warfarin, dicumarol; note: antiplatelet drugs
             including aspirin and clopidogrel are permitted) and investigational medications
             within 4 weeks of screening

          -  Allergy or sensitivity to medications required to safely undergo AeriSeal System
             treatment

          -  Participation in an investigational study of a drug, biologic, or device not currently
             approved for marketing within 30 days prior to the screening visit

          -  Body mass index &lt; 15 kg/m2 or &gt; 35 kg/m2

          -  Female patient pregnant or breast-feeding or planning to be pregnant in the next year

          -  Significant comorbidity that carries prohibitive risks or is associated with less than
             2-year expected survival, including any of the following:

               -  HIV/AIDS

               -  Active malignancy

               -  Stroke or TIA within 12 months of screening

               -  Myocardial infarction within 12 months of screening

               -  Congestive heart failure within 12 months of screening defined at clinical
                  evidence of right or left hear failure or left ventricular ejection fraction &lt;
                  45% on echocardiogram

          -  Any condition that the Investigator believes would interfere with the intent of the
             study or would make participation not in the best interest of the patient such as
             alcoholism, high risk for drug abuse or noncompliance in returning for follow-up
             visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janine McDermott, MS CCRP</last_name>
    <role>Study Director</role>
    <affiliation>Aeris Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka GmbH</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Donaustauf</name>
      <address>
        <city>Donaustauf</city>
        <zip>93093</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachkliniken Muenchen - Gauting</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Hamburg-Harburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik am Uniklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sana Kliniken Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>23560</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik Grosshadern</name>
      <address>
        <city>Munchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah - Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2012</study_first_submitted>
  <study_first_submitted_qc>January 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2012</study_first_posted>
  <last_update_submitted>November 13, 2013</last_update_submitted>
  <last_update_submitted_qc>November 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gold Stage III</keyword>
  <keyword>Gold Stage IV</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Lung Volume Reduction Surgery</keyword>
  <keyword>LVRS</keyword>
  <keyword>Bronchoscopic Lung Volume Reduction</keyword>
  <keyword>BLVR</keyword>
  <keyword>Upper Lobe Predominant</keyword>
  <keyword>ULP</keyword>
  <keyword>Heterogeneous</keyword>
  <keyword>Homogeneous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

